Literaturverzeichnis
zum Titelthema „Diagnostik und Therapie des Morbus Crohn“
Bayerisches Ärzteblatt 9/2015, Seite 408 ff.
von Dipl.-Vw. Dr. univ. Simon Hirschmann, Professor Dr. Raja Atreya
und Professor Dr. Markus Neurath

1. *Albert JG, Kotsch J, Köstler W et al*. Course of Crohn's disease prior to establishment of the diagnosis. Z Gastroenterol. 2008 Feb;46(2):187-92.
2. *Timmer A*. Epidemiologie der CED. In: Hoffmann JC, Kroesen AJ, Klump B Hrsg Chronisch entzündliche Darmerkrankungen – Handbuch für die Praxis. 2. Aufl. Stuttgart, New York: Georg Thieme Verlag; 2009: 8 – 24
3. *Molodecky NA*, *Soon IS*, *Rabi DM et al.* Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46 – 54 e42; quiz e30
4. *Loftus CG*, *Loftus EV Jr*, *Harmsen WS et al.* Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis 2007; 13: 254 – 261
5. *Stark R*, *Konig HH*, *Leidl R*. Costs of inflammatory bowel disease in Germany. PharmacoEconomics 2006; 24: 797 – 814
6. *Geerling BJ*, *Badart-Smook A*, *Stockbrugger RW et al.* Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. Eur J Clin Nutr 2000; 54: 514 – 521
7. *Filippi J*, *Al-Jaouni R*, *Wiroth JB et al.* Nutritional deficiencies in patients with Crohn's disease in remission. Inflamm Bowel Dis 2006; 12: 185 – 191
8. *van Rheenen PF*, *Van de Vijver E*, *Fidler V*. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369
9. *Hommes DW*, *Sterringa G*, *van Deventer SJ et al.* The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis 2004; 10: 245 – 250
10. *Migaleddu V*, *Scanu AM*, *Quaia E et al.* Contrast-enhanced ultrasonographic evaluation of inflammatory activity in Crohn's disease. Gastro- enterology 2009; 137: 43 – 52
11. *Pallotta N*, *Vincoli G*, *Montesani C et al.* Small intestine contrast ultrasonography (SICUS) for the detection of small bowel complications in crohn's disease: a prospective comparative study versus intraoperative findings. Inflamm Bowel Dis 2012; 18: 74 – 84
12. *Schmidt T*, *Hohl C*, *Haage P et al.* Phase-inversion tissue harmonic imaging compared to fundamental B-mode ultrasound in the evaluation of the pathology of large and small bowel. Eur Radiol 2005; 15: 2021 – 2030
13. *Maconi G*, *Sampietro GM*, *Parente F et al.* Contrast radiology, computed tomography and ultrasonography in detecting internal fistulas and intra-abdominal abscesses in Crohn's disease: a prospective comparative study. Am J Gastroenterol 2003; 98: 1545 – 1555
14. *Annunziata ML, Caviglia R, Papparella LG et al.* Upper gastrointestinal involvement of Crohn's disease: a prospective study on the role of upper endoscopy in the diagnostic work-up. Dig Dis Sci. 2012 Jun;57(6):1618-23.
15. *Vernier-Massouille G*, *Balde M*, *Salleron J et al.* Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008; 135: 1106 – 1113
16. *Cosnes J*, *Gower-Rousseau C*, *Seksik P et al.* Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785 – 1794
17. *Bernstein CN*, *Blanchard JF*, *Kliewer E et al.* Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001; 91: 854 – 862

18. *Jess T*, *Gamborg M*, *Matzen P et al.* Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005; 100: 2724 – 2729
19. *Canavan C*, *Abrams KR*, *Mayberry J*. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 2006; 23: 1097 – 1104
20. *Rubio CA*, *Dick EJ Jr*, *Orrego A et al.* Further studies on the frequency and length of the glandulo-metaplastic esophageal mucosa in baboons. In Vivo 2009; 23: 955 – 958
21. *Laukoetter MG*, *Mennigen R*, *Hannig CM et al.* Intestinal cancer risk in Crohn's disease: a meta-analysis. J Gastrointest Surg 2011; 15: 576 – 583
22. *Friedman S*, *Rubin PH*, *Bodian C et al.* Screening and surveillance colonoscopy in chronic Crohn's colitis: results of a surveillance program spanning 25 years. Clin Gastroenterol Hepatol 2008; 6: 993 – 998; quiz 953 – 994
23. *Lichtenstein GR*, *Feagan BG*, *Cohen RD et al.* Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012; 107: 1409 – 1422
24. *Lichtenstein GR*, *Feagan BG*, *Cohen RD et al.* Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621 – 630
25. *Toruner M*, *Loftus EV Jr*, *Harmsen WS et al.* Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;
1. 134: 929 – 936
26. *Fidder H*, *Schnitzler F*, *Ferrante M et al.* Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501 – 508
27. *Crum NF*, *Lederman ER*, *Wallace MR*. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 2005; 84: 291 – 302
28. *Gaemperli A*, *Hauser T*, *Speck R*. Risk of infection during treatment with tumor necrosis factor-alpha inhibitors. Zeitschrift für Rheumatologie 2006; 65: 24 – 28, 30-21
29. *Gupta G*, *Lautenbach E*, *Lewis JD*. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 1483 – 1490
30. *Viget N*, *Vernier-Massouille G*, *Salmon-Ceron D et al.* Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008; 57: 549 – 558
31. *Tsiodras S*, *Samonis G*, *Boumpas DT et al.* Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clinic proceedings 2008; 83: 181 – 194
32. *Beaugerie L*, *Brousse N*, *Bouvier AM et al.* Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617 – 1625
33. *Mackey AC*, *Green L*, *Liang LC et al.* Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265 – 267
34. *Deepak P*, *Sifuentes H*, *Sherid M et al.* T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am J Gastro- enterol 2013; 108: 99 – 105
35. *Rutgeerts P*, *Feagan BG*, *Lichtenstein GR et al.* Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402 – 413
36. *Sandborn WJ*, *Colombel JF*, *Schreiber S et al.* Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011; 17: 141 – 151
37. *Colombel JF*, *Sandborn WJ*, *Rutgeerts P et al.* Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52 – 65

38. *Schreiber S*, *Khaliq-Kareemi M*, *Lawrance IC et al.* Maintenance therapy with certolizumab pegol for Crohn's disease. The New England journal of medicine 2007; 357: 239 – 250
39. *Sandborn WJ*, *Rutgeerts P*, *Enns R et al.* Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829 – 838
40. *Sandborn WJ*, *Abreu MT*, *D'Haens G et al.* Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010; 8: 688 – 695 e682
41. *Allez M*, *Vermeire S*, *Mozziconacci N et al.* The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010; 31: 92 – 101
42. *Sutherland LR*, *Ramcharan S*, *Bryant H et al.* Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990; 98: 1123 – 1128
43. *Munkholm P*, *Langholz E*, *Davidsen M et al.* Disease activity courses in a regional cohort of
2. Crohn's disease patients. Scand J Gastroenterol 1995; 30: 699 – 706
44. *Duricova D*, *Pedersen N*, *Elkjaer M et al.* Overall and cause-specific mortality in Crohn's disease: a meta-analysis of population-based studies. Inflamm Bowel Dis 2010; 16: 347 – 353
45. *Beaugerie L*, *Seksik P*, *Nion-Larmurier I et al.* Predictors of Crohn's disease. Gastroenterology 2006; 130: 650 – 656
46. *Loly C*, *Belaiche J*, *Louis E*. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008; 43: 948 – 954
47. *Kruis W*, *Katalinic A*, *Klugmann T et al.* Predictive factors for an uncomplicated long-term course of Crohn's disease: a retrospective analysis. Journal of Crohn's & colitis 2013; 7: e263 – e270
48. *Mahid SS*, *Minor KS*, *Stromberg AJ et al.* Active and passive smoking in childhood is related to the development of inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 431 – 438
49. *Mahid SS*, *Minor KS*, *Soto RE et al.* Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clinic proceedings 2006; 81: 1462 – 1471
50. *Timmer A*, *Sutherland LR*, *Martin F*. Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroente- rology 1998; 114: 1143 – 1150
51. *Kane SV*, *Flicker M*, *Katz-Nelson F*. Tobacco use is associated with accelerated clinical recurrence of Crohn's disease after surgically induced remission. J Clin Gastroenterol 2005; 39: 32 – 35
52. *Johnson GJ*, *Cosnes J*, *Mansfield JC*. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther 2005; 21: 921 – 931
53. *Cosnes J*, *Carbonnel F*, *Beaugerie L et al.* Effects of cigarette smoking on the long-term course of Crohn's disease. Gastroenterology 1996; 110: 424 – 431
54. *Breuer-Katschinski BD*, *Hollander N*, *Goebell H*. Effect of cigarette smoking on the course of Crohn's disease. Eur J Gastroenterol Hepatol 1996; 8: 225 – 228
55. *Swoger JM*, *Regueiro M*. Preventive therapy in postoperative Crohn's disease. Curr Opin Gastroenterol 2010; 26: 337 – 343
56. *Ng SC*, *Kamm MA*. Management of postoperative Crohn's disease. Am J Gastroenterol 2008; 103: 1029 – 1035
57. *Kamm MA, De Cruz PP, Wright EK, et al.* Optimising post-operative Crohn's disease management: best drug therapy alone versus endoscopic monitoring, disease evolution, and faecal calprotectin monitoring. The POCER study. J Crohns Colitis. 2014;8(Suppl 1):S13.

58. *Navarro FA*, *Hanauer SB*, *Kirschner BS*. Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease. J Pediatr Gastroenterol Nutr 2007; 45: 312 – 318
59. *Heuschkel RB*, *Menache CC*, *Megerian JT et al.* Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 2000; 31: 8 – 15
60. *Eshuis EJ*, *Slors JF*, *Stokkers PC et al.* Long-term outcomes following laparoscopically assisted versus open ileocolic resection for Crohn's disease. Br J Surg 2010; 97: 563 – 568
61. *Lowney JK DD*, *Birnbaum EH*, *Kodner IJ et al.* Is there any difference in recurrence rates in laparoscopic ileocolic resection for Crohn's disease compared with conventional surgery? A long-term, follow-up study. Dis Colon Rectum 2006; 49: 58 – 63
62. *Graadal O*, *Nygaard K*. Crohn disease. Long-term effects of surgical treatment. Tidsskr Nor Laegeforen 1994; 114: 1603 – 1605
63. *Nordgren SR*, *Fasth SB*, *Oresland TO et al.* Long-term follow-up in Crohn's disease. Mortality, morbidity, and functional status. Scand J Gastroenterol 1994; 29: 1122 – 1128
64. *Weston LA*, *Roberts PL*, *Schoetz DJ Jr et al.* Ileocolic resection for acute presentation of Crohn's disease of the ileum. Dis Colon Rectum 1996; 39: 841 – 846
65. *Kim NK*, *Senagore AJ*, *Luchtefeld MA et al.* Long-term outcome after ileocecal resection for Crohn's disease. Am Surg 1997; 63: 627 – 633
66. *Solberg IC*, *Vatn MH*, *Hoie O et al.* Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007; 5: 1430 – 1438
67. Louis E, Collard A, Oger AF et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49: 777–782
68. *Buchanan GN, Owen HA, Torkington J et al.* Long-term outcome following looseseton technique for external sphincter preservation in complex anal fistula. Br J Surg 2004; 91: 476–480
69. *Takeuchi K, Smale S, Premchand P et al.* Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 196–202
70. *Fonager K, Sorensen HT, Olsen J et al.* Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol 1998; 93: 2426–2430
71. *Baiocco PJ, Korelitz BI.* The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol 1984; 6: 211–216
72. *Larzilliere I, Beau P.* Chronic inflammatory bowel disease and pregnancy.Case control study. Gastroenterologie clinique et biologique 1998; 22: 1056–1060
73. *Miller JP.* Inflammatory bowel disease in pregnancy: a review. J R Soc Med 1986; 79: 221–225
74. *NarendranathanM, Sandler RS, Suchindran CM et al.* Male infertility in inflammatory bowel disease. J Clin Gastroenterol 1989; 11: 403–406
75. *O'Morain C, Smethurst P, Dore CJ et al.* Reversible male infertility due to sulphasalazine: studies in man and rat. Gut 1984; 25: 1078–1084
76. *Birnie GG, McLeod TI,Watkinson G.* Incidence of sulphasalazine-induced male infertility. Gut 1981; 22: 452–455
77. *Levi AJ, Fisher AM, Hughes L et al.* Male infertility due to sulphasalazine. Lancet 1979; 2: 276–278
78. *Toth A.* Reversible toxic effect of salicylazosulfapyridine on semen quality. Fertil Steril 1979; 31: 538–540
79. *van der Woude CJ, Kolacek S, Dotan I et al.* European evidenced-based consensus on reproduction in inflammatory bowel disease. Journal of Crohn's & colitis 2010; 4: 493–510

80. *Raine T.* Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United European Gastroenterol J. 2014 Oct;2(5):333-44
81. *Dignass A et al.* Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: current management; Journal of Crohn's and Colitis (2012) 6, 1004
82. *Peyrin-Biroulet L*, *Ferrante M*, *Magro F et al.* Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. Journal of Crohn's & colitis 2011; 5: 477 – 483
83. *D'Haens G*, *Sandborn WJ*, *Feagan BG et al.* A review of activity indices and efficacy end
3. points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763 – 786
84. *Louis E*, *Mary JY*, *Vernier-Massouille G et al.* Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63 – 70 e65; quiz e31
85. *Mazzuoli S, Guglielmi FW, Antonelli E et al.* Definition and evaluation of mucosal healing in clinical practice Dig Liver Dis. 2013 Dec;45(12):969-77.
86. *Neurath MF* Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014 May;14(5):329-42.
87. *Sandborn WJ, Gasink C, Gao LL et al.* Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012 Oct 18;367(16):1519-28.
88. *Atreya R, Neumann H, Neufert C et al.* In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease. Nat Med. 2014 March; 20(3): 313–318.